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Abstract
Background: Bone marrow mononuclear cell (BMMC) transplantation is a promising therapy for cerebral ischemia;
however, little is known if its therapeutic efficacy may be improved by co-administration of potential modulatory
factors in vivo. To explore this possibility, the present study examined the effect of BMMCs and G-CSF on cell
proliferation, early neuronal development and neurological function recovery in experimental cerebral ischemia
relative to controls that received neither treatment.
Result: Ischemia/infarct area was significantly reduced in BMMCs+G-CSF group relative to animal groups treated
with BMMCs only, G-CSF only or saline. Transplanted BMMCs were found to colocalize with the proliferative cell
nuclear antigen (PCNA) and the immature neuronal marker doublecortin (DCX). The BMMCs+G-CSF group showed
increased numerical density of cells expressing PCNA and DCX, improved performance in adhesive sticker removal
test and reduced neurological function severity scores relative to other groups in a time-dependent manner.
Conclusion: BMMCs and G-CSF co-administration exhibits synergistic beneficial effect over time. This effect could
be at least partially related to increased proliferation and differentiation of bone marrow stem cells and enhanced
host brain regeneration and functional recovery. The results suggest that G-CSF can increase the therapeutic
efficacy of BMMCs transplantation in an experimental mouse model of cerebral ischemia.
Background
Bone marrow mononuclear cells (BMMCs) are a popula-
tion of pluripotent progenitor cells with potential thera-
peutic value to boost cell repair and regeneration in some
disease conditions. In the context of neurology, BMMCs
have been shown to promote neuronal regeneration in
ischemic cerebrovascular diseases [1,2]. BMMCs can be
modulated by various cellular or hormonal factors, sug-
gesting that their putative therapeutic efficacy might be
enhanced via co-administration of these factors in vivo.
Granulocyte colony stimulating factor (G-CSF) is one of
such biological modulators, and has been shown to
enhance proliferation and mobilization of BMMCs in
some disease models [3]. For instance, Jin et al [4] have
demonstrated that G-CSF promotes the migration of bone
marrow cells into injured mouse liver. We have previously
shown that transplanted BMMCs may relocate to the cere-
brum following ischemic injury [5]. Accordingly, we
hypothesize that G-CSF can promote BMMCs homing to
ischemic cerebrum, and improve histological outcome and
neurological function recovery. To explore these possibili-
ties, BMMCs were isolated from the bone marrow of
BALB/c mice, double labeled in vitro with the membrane
fluorescent dye PKH26 and the nuclear fluorescence
probe 4’, 6-diamidino-2-phenylindole (DAPI). These pre-
labeled BMMCs were transplanted into host mice received
either G-CSF or vehicle following experimental cerebral
ischemia. Therapeutic effects were evaluated by assessing
infarct size, integration of transplanted BMMCs in the
brain, recovery of neurological function.
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Flow cytometric analysis of donor BMMCs
The BMMC fraction of bone marrow can be a mix of dif-
ferent cellular populations. We characterized BMMCs
harvested from the donor mice to obtain their surface
antigen profile by fluorescence-activated cell sorting
(FACS). The marrow cell markers CD34, CD44, CD45
and Sca-1 were used to label BMMCs, and the percen-
tage of each type were estimated. In average, donor
BMMCs exhibited CD34, CD44, CD45 and Sca-1 antigen
signals at 93.5%, 45.8%, 80.9% and 1.9%, respectively
(Table 1). These data are consistent with the signature
surface antigen profile of bone marrow stem cells
reported by Okada et al [6].
Effect of G-CSF and BMMCs on cerebral infarct size
In the present study, effect of BMMC transplantation
and G-CSF co-administration following experimental
cerebral ischemia was comparatively studied among 4
groups of mice. Two groups of MCA occluded animals
received tail vein infusion of BMMCs with (BMMCs+G-
C S Fg r o u p )a n dw i t h o u t( B M M C sg r o u p )G - C S Fc o -
administration. Two other groups of MCA occluded
animals were not given BMMC transplantation but
received either G-CSF (G-CSF group) or saline (saline
group) injection to serve as non-transplant controls (S-
Figure 1). We assessed gross cerebral infarct volume
among the 4 groups of animals. The mean infarct
v o l u m e( 8 4 . 3±1 . 4m m
3) in the BMMCs+G-CSF group
was significantly smaller than that in the BMMCs
(143.5 ± 1.5 mm
3), G-CSF (148.2 ± 2.1 mm
3) and saline
(186.7 ± 1.8 mm
3) groups (p < 0.0001, F = 2411, df = 3,
12; one-way ANOVA analysis) (Figure 1). Bonferroni’s
multiple comparison tests indicated a statistically signifi-
cant difference between the BMMCs (p < 0.001) and G-
CSF (p < 0.001) groups relative to controls. Also, the
infarct size in the BMMCs group was smaller relative to
G-CSF group (p < 0.05).
Effect of G-CSF and BMMCs on PCNA expressing cells
PKH26-labeled cells emit red fluorescence under 551
nm light excitation, whereas the blue fluorescence of
DAPI is detectable using 405 nm light excitation. Thus,
donor BMMCs double-labeled in vitro by PKH26 and
DAPI can be reliably located in the host brain. Overall,
no any PKH26 or DAPI-labeled cells were detected in
the brains of mice that did not receive BMMC tail infu-
sion (data not shown, but see Figure 2 and Figure 3 in
Zhang et al., 2010)[5]. On the contrary, PKH26 and
DAPI double labeled cells were found in mice with
BMMC transplantation.
One potential effect of G-CSF on BMMCs may
involve the proliferative capability of these transplanted
cells. We therefore assessed PKH26/DAPI cells co-
expressing PCNA, a nuclear cell proliferation marker
[7], by confocal fluorescent microscopy. PKH26, DAPI
and PCNA triple-labeled cells were found largely around
the border of the ischemic and healthy cortical areas
(Figure 2A-E). In order to compare cell proliferative rate
among the 4 animal groups, we semi-quantitatively
assessed the abundance of PCNA labeled cells at day 1,
7, 14 and 28 after MCAO by immunohisochemistry
u s i n gD A Ba sac h r o m o g e n( F i g u r e2 F ) .T h ed e n s i t yo f
PCNA positive cells was significantly higher in the
BMMCs+G-CSF group relative to other groups at the 4
surviving time points (Figure 2G). Bonferroni’s multiple
comparison tests indicated that at the 1 day surviving
point a statistically significant difference existed between
BMMCs+G-CSF group and the remaining 3 groups, but
not between the BMMCs, G-CSF and saline groups. At
other surviving points, there was statistically significant
difference between the saline group and each of the
treatment groups (the BMMCs+G-CSF, BMMCs or G-
CSF group). In addition, the density of PCNA labeled
cells was increased with time in the BMMCs+G-CSF (p
< 0.001, F = 118.7), BMMCs (p < 0.001, F = 27.54) and
G-CSF (p <0.001, F = 20.76) groups, but this change
was not found in the saline group (p = 0.105, F = 2.55)
(Figure 2G).
Effect of G-CSF and BMMCs on DCX expressing cells
Recent studies suggest that transplanted BMMCs may
transdifferentiate into neurons in ischemic or trauma-
tized brain [8,9]. We have previously shown that PKH26
pre-labeled BMMCs may colocalize with doublecortin
(DCX), a marker of immature neurons, in the ischemic
host cerebrum [5]. In the present study, we confirmed
that PKH26/DAPI double-labeled BMMCs could be co-
labeled for DCX in animals surviving 14 and 28 days
(Figure 3A-E). In both immuofluorescent and DAB (Fig-
ure 3F) preparations, DCX positive cells occurred mostly
around the infarct border.
Table 1 Surface antigen profile of donor BMMCs by flow cytometry
Marker Mouse#1(%) Mouse#2(%) Mouse#3(%) Average (%) S.E.M
CD34 94.4 90.3 95.7 93.5 2.3
CD44 47.7 45.2 44.6 45.8 1.3
CD45 80.1 79.5 83.2 80.9 1.6
Sca-1 1.4 2.6 1.8 1.9 0.5
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cells (in DAB preparation) in the 4 groups of animals at
day 1, 7, 14 and 28 post MCAO (Figure 3G). The density
of DCX-labeled cells increased with surviving time in the
BMMCs+G-CSF, BMMCs and G-CSF groups (p <
0.0001, one-way ANOVA analysis), but not in the saline
group (p = 0.1057). At the 7, 14 and 28 days surviving
time points, the density of DCX+ cells in the BMMCs
+G-CSF, BMMCs and G-CSF groups was higher relative
to the saline group (p = 0.021 to p < 0.0001). Bonferroni’s
multiple comparison tests also showed statistically signif-
icant difference between the saline group and each of the
other groups, and between the BMMCs+G-CSF group
a n dt h eB M M C so rG - C S Fg r o u pa t1 4a n d2 8s u r v i v i n g
days (Figure 3G).
Effect of G-CSF treatment on neurological function
recovery
O v e r a l l ,t h et i m eam o u s es p e n tt or e m o v et h ea d h e s i v e
paper was dramatically increased after relative to before
MCAO. Thus, at 1 day after MCAO, the adhesive
removal times was longer but comparable among the 4
groups of occluded animals relative to pre-surgical basal
scores (Figure 4A). During the recovery phase, BMMC
transplanted mice received G-CSF used less time to
remove the adhesive papers as compared to other groups
at 7 to 28 days after MACO (Figure 4A) (p < 0.05 to p <
0.001, as determined by Bonferroni’s multiple compari-
son tests in one-way ANOVA analysis). Also, the
BMMCs group spent increasingly less time to remove the
sticker during the recovery phase (p < 0.0001, F = 1420,
df = 4, 25, one-way ANOVA).
The neurological severity scores (NSS) were high but
similar (p > 0.05) among the 4 animal groups as assessed
at day 1 after MCAO (Figure 4B). During the recovery
phase, the scores showed a trend of reduction with time
in all groups. The BMMCs+G-CSF group exhibited sig-
nificantly lower scores relative to the BMMCs only group
as well as the two animal groups that did not receive the
bone marrow cells at 7 to 28 days surviving points (p <
0.05 to p < 0.001, Bonferroni’s multiple comparison
tests). The time-dependent decline in neurological sever-
ity scores was confirmed by statistical analysis (p <
0.0001, F = 119.8, df = 3, 19, one-way ANOVA).
Discussion
Transplanted BMMCs proliferate and transdifferentiate in
ischemic cerebrum
Bone marrow stem cell therapy has merged as a promis-
ing treatment for acute brain trauma. In practice, donor
bone marrow cells are a mix of cellular components,
with the BMMC fraction being considered a key player
in the beneficial therapeutic efficacy in neuronal recov-
ery. Our fluorescence activated cell sorting analysis sug-
gests a phenotype of the transplanted cells being
hematopoietic stem cells in nature, based on their
expression of CD34 (93. 5%), CD44 (45.8%), CD45
(80.9%) and Sca-1(1.9%) [10]. The use of PKH26 and
Figure 1 Representative images of TTC-stained brain slices and infarct volume analysis at 28 days post middle cerebral artery
occlusion. Representative brain slice images (left) were taken at 24 hours following TTC staining. Bar graph on the right shows corrected infarct
volumes (CIV) among 4 animal groups. For each brain the CIV value was calculated from slices at 2-mm intervals. Mean infarct volumes are
reduced in BMMCs+G-CSF groups (84.3 ± 1.4) relative to BMMCs group (143.5 ± 1.5), G-CSF group (148.2 ± 2.1) and Saline group (186.7 ± 1.8); as
well as between the BMMCs or G-CSF group relative to the saline group (Bonferroni’s post-tests).
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Page 3 of 9DAPI double fluorescent labeling allow us to trace the
homing of BMMCs in the recipient mouse brain. Con-
sistent with an early report [11], immunofluorescent co-
labelings for PCNA and DCX suggest that some of
these pre-labeled BMMCs are undergoing proliferation
and appear to trans-differentiate into immature neurons
in the ischemic cerebrum.
BMMCs and G-CSF exhibit synergistic effect on cell
proliferation and early neuronal development in ischemic
cerebrum
Improving the therapeutic efficacy of BMMC transplant
may be of future clinical relevance. Data from the present
study support that G-CSF, a biological regulator of
BMMCs in vivo, may exhibit beneficial modulatory effect
on both the transplanted bone marrow cells as well as
the histological and neurological outcome in the host
animals in an acute model of cerebral ischemia or infarc-
tion. Densitometric analyses show that the amount of
PCNA and DCX-expressing cells are increased in the cer-
ebral cortex in G-CSF-treated recipient mice relative to
the BMMCs and G-CSF groups, in addition to the saline
group. Therefore, it appears that BMMCs transplantation
and G-CSF administration each could promote cell pro-
liferation and DCX expression in the ischemic cortex
[12], while BMMCs and G-CSF co-treatment elicits a
Figure 2 Colocalization of transplanted BMMCs with PCNA and densitometry of PCNA expressing cells at various surviving times.
Panels A to E are representative confocal images showing that transplanted BMMC, pre-labeled by PKH26 (red) and DAPI (blue), co-localize with
proliferative cell nuclear antigen (PCNA, green). (F) illustrates PCNA immmunoreactive cells visualized with the DAB method around the infarct
border of the infarct area. (G) shows semi-quantitative data of PCNA positive cells at different time points in the 4 groups of animals. ANOVA
table on the right denotes statistical analysis data on the time course effect (longitudinal factor) in the 4 animal groups as well as treatment
effect (transversal factor) at the 4 time points.
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and G-CSF are both positive modulatory factor in the
homing and potential neuronal trans-differentiation of
hemopoietic stem cells in ischemic cerebral cortex.
BMMCs and G-CSF exhibit synergistic effect on
histological and neurological outcomes
G-CSF administration appears to also reduce the cere-
bral infarct size according to our assessment on brain
slices. In fact, this effect is most noticeable in animals
received BMMC transplant as compared to ischemic
animals without BMMC treatment. Thus, BMMC infu-
sion and G-CSF treatment appear to exhibit synergeric
protective effect in lesioned host animals. In parallel
with the improved histological outcome, animals
received G-CSF treatment show better neurological
function recovery.
Mechanistic consideration for the effect of BMMCs and
G-CSF in ischemic cerebrum
The precise mechanism by which G-CSF may influence
transplanted and host BMMCs, or other cellular
Figure 3 Colocalization of transplanted BMMCs with DCX and densitometry of DCX expression at various surviving times. Panels A to E
show that transplanted BMMC pre-labeled by PKH26 (red) and DAPI (blue) co-localize with doublecortin (DCX, green) in the cerebral cortex of a
recipient mouse (14 days surviving). (F) demonstrates DCX immunoreactivity visualized with the DAB method localizing around the border of the
infarct area. (G) shows semi-quantitative measurements of DCX positive cells in MCA occluded mice at different time points. ANOVA table on the
right summarizes statistical analysis data on the time course effect (longitudinal factor) in the 4 animal groups as well as treatment effect
(transversal factor) at the 4 time points.
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be elucidated. However, a large body of basic and clini-
cal studies suggest that G-CSF can mobilize hemopoie-
tic stem cells, therefore might improve their delivery
and differentiation in bodily tissue [12-14]. It is known
that G-CSF can promote cell proliferation including
stem cell proliferation and their differentiation into
neutrophils, eosinophils and mononuclear macro-
phages. This pro-proliferative or cell trophic effect is
probably mediated by G-CSF receptor (G-CSF-R),
which is especially enriched on the cell surface of bone
marrow stem cells [15,16]. G-CSF-R activation initiates
signal transduction through proteins including Jak,
Lyn, STAT and Erk1/2, which may cascade cell prolif-
eration, differentiation and maturation [17,18]. Via
s u c ham o d eG - C S Fm a yh e l pt r a n s p l a n t e do rh o s t
blood stem cells home to the injured brain and
potentiate neuronal regeneration [4,19]. Of note, some
authors suggest that G-CSF may facilitate the migra-
tion and localization of neuronal stem cells into
injured areas [20]. Therefore, G-CSF administration
might also play a role in promoting intrinsic neuronal
self-repair in the brain.
In summary, this work demonstrates that G-CSF
administration facilitates the therapeutic efficacy of
BMMC transplantation in histological and neurological
outcomes in a mouse model of focal cerebral ischemia.
Because autologous BMMC transplantation may be use-
ful in the treatment of cerebral injury including ische-
mia, co-administration of G-CSF may be considered a
promising adjunct therapy in clinical practice. Further
basic and clinical investigations are warranted to explore
the molecular mechanism underlying the effect of com-
bined G-CSF administration and BMMCs transplanta-
tion in cerebral ischemia.
Conclusions
The present study shows that G-CSF may promote the
homing, proliferation and potentially neuronal differentia-
tion of transplanted BMMCs in ischemic mouse cerebral
cortex. G-CSF administration also appears to improve the
efficacy of BMMC transplantation by reducing cerebral
infarct size and enhancing neurology function recovery.
T h ed a t ar a i s eap o s s i b i l i t yo fu s i n gB M M Ct r a n s p l a n t a -
tion together with G-CSF administration in clinical treat-
ment of cerebral ischemia.
Methods
Experimental animals and reagents
Inbred BALB/c mice at 8 to 10 weeks of age, of male or
female gender, with a bodyweight ranging between 18 to
20 g, were purchased from the Animal Center of the
Second Affiliated Hospital of Harbin Medical University.
Figure 4 Neurological evaluation of mice prior to and after
middle cerebral artery occlusion. The upper graph (A) shows the
average time scores for adhesive-removal in the 4 animal groups at
various surviving points. Mice with BMMCs transplantation
combined with G-CSF administration spend less time to remove the
adhesive paper on their forearm relative to other groups. The low
graph (B) plots the modified neurological severity scores (mNSS) in
the 4 animal groups at different time points. The extent of
neurological function impairment is significantly less in the BMMCs-
G-CSF group relative to other groups, and also reduces with
increasing surviving time overall. No differences exist before and at
day one after ischemic lesion for either adhesive removal or mNSS
scores.
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before and after the experimental procedures. Primary
antibodies and secondary detection systems, as well as
major reagents, used in the present study are listed in
Table 2.
Experimental groups
To evaluate the effect of G-CSF administration and BMMC
transplantation, mice were divided into donor group (n =
14, for BMMC donation) and recipient group with focal
cerebral ischemia. The recipient group was then sub-
divided. Thus, Group #1 animals (BMMCs+G-CSF)
received BMMCs transplantation combined with G-CSF
injection (30 μg/kg/d, i.p.). Group #2 animals (BMMCs)
received BMMCs without G-CSF injection. Group #3 ani-
mals (G-CSF) received G-CSF injection (30 μg/kg/d, i.p.)
without BMMCs treatment. Group #4 was treated with 0.3
ml of saline (0.9% NaCl, i.p.) as vehicle control. For group
#1, daily G-CSF injection (30 μg/kg/d, i.p.) started after
BMMC transplantation and continued once a day for four
successive weeks. The same G-CSF administration protocol
was used for group #3 (S-Figure 1). Four animals per group
were used for evaluation of infarct size and 4 animals per
group were used for histology and immunohistochemistry.
Isolation, in vitro fluorescent labeling and transplantation
of BMMCs
As shown previously, BMMCs can be isolated and
labeled in vitro prior to transplantation [11,21]. Briefly,
the femoral bones were aseptically harvested from
donor mice under anaesthesia (sodium pentobarbital,
100 mg/kg, i.p.). After resection, the bone marrow in
the medullary cavity was bathed with saline containing
heparin (50 U/ml). The bone marrow cells were
harvested and suspended in lymphocyte isolation med-
ium under sterile conditions. After dilution with 2 ml
phosphate-buffered saline (PBS, 0.01 mol/L, pH = 7.4)
at 1:1 ratio, cells were slowly added to yield a relative
density of 1.077 g/cm
3, which was followed by centrifu-
gation at 2000 rpm for 20 minutes. The cells were har-
vested, washed with PBS three times, and centrifuged at
1200 rpm for 10 minutes. The second layer of cells in
the centrifugation tube was removed and re-suspended
with DMEM/F12 medium (DMEM/F12, 15% PBS,
100,000 U/L penicillin, pH = 7.4) to provide a cell den-
sity > 5 × 10
8 cells/L. Then BMMCs were pre-labeled
by PKH26 and DAPI according to the manufacturer’s
instruction [22]. The final density of double-labeled cell
suspension was adjusted to 3 × 10
7 cells/ml. The viabi-
lity of BMMCs was greater than 95% measured by try-
pan blue exclusion. For a given recipient mouse 1 × 10
7
double-labeled BMMCs were injected via the tail vein.
Identification of double-labeled cells by flow cytometric
analysis
Putative BMMCs double labeled by PKH26 and DAPI (1
×1 0
6 cells/ml) were incubated in 2% fetal bovine serum
in PBS at 4°C for 20 minutes with 1 μlo fm o u s em o n o -
clonal antibodies specific for CD34, CD44, CD45, Sca-1
or treated with normal mouse serum as a control. Sam-
ples were then analyzed by FACS Calibur with Cell-
Quest software (Becton Dickinson, USA).
BALB/c mice model of focal cerebral ischemia
In order to establish the experimental murine model of
focal cerebral ischemia, the middle cerebral artery was
occluded with electric coagulation following a modified
craniectomy [23]. The surgical procedures have been
described previously in detail [11,21].
Neurological tests
For adhesive removal tests, square-shaped pieces (100
mm
2) of adhesive-backed paper were used as bilateral
tactile stimuli by placing on the distal-radial area of the
wrist of each forelimb. Mice were pre-trained for 1
week before tests and assessed basal level of time scores
for adhesive removal before MCA occlusion. Mice were
tested in 3 trials to measure the mean time to remove
the adhesive papers, with a cutoff time of 300 seconds.
The neurological severity scores (NSS) were modified
and calculated following the method of Lu D et al [11].
The modified neurological severity scores (mNSS) are
given according to animal’s performance on motor (mus-
cle status, abnormal movement), sensory (visual, tactile,
and proprioceptive) and reflex tests [22,23]. Points reflect
the extent of inability to perform a given test; thus, higher
scores represent poorer neurological function or presum-
ably greater injury.
Table 2 Primary antibodies and major biochemical
reagents used in this study
Antibody or Biochemical
Reagents
Source Product
#
Dilution
Mouse anti-PCNA antibody Santa
Cruz
BM 0104 1:200
Mouse anti-DCX antibody Santa
Cruz
Sc-2024 1:100
PKH26 Sigma PKH26PCL 1:1000000
DAPI Roche 46190 5 μg/ml
Alexa Fluor
® 488 Invitrogen A11055 1:200
FITC rat IgG 2a Isotype Biolegend 400505 1:200
APC rat IgG 2a Isotype ctrl Biolegend 400511 1:200
PE rat IgG 2b Isotype ctrl Biolegend 118419 1:200
Percp rat IgG 2b Isotype ctrl. Biolegend B118419 1:200
FITC anti-mouse LY-6A/EC Sca-1 Biolegend 122505 1:100
APC anti-mouse CD34 Biolegend 119309 1:100
PE anti-mouse/human CD44 Biolegend 103007 1:100
Percp anti-mouse CD45 Biolegend 103129 1:100
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Mice were sacrificed and perfused transcardially for 2
minutes at 120 mmHg with 4% paraformaldehyde in
0.01 M phosphate-buffered saline (pH 7.4, PBS) via a
left ventricular stab under overdose pentobarbital
anesthesia (sodium pentobarbital 100 mg/kg, i.p.). The
brains were dissected out and cryoprotected in 30%
sucrose at 4°C overnight, embedded in optimal cutting
temperature compound, frozen, and prepared into 8-
μm-thick frozen sections using a cryostat.
Histological and morphological evaluation of BMMC
homing
To assess the rate of proliferation and survival of cells
after BMMC transplantation, a one in eight series of
sections from each brain was collected randomly to
identify PKH26 and DAPI double positive cells. Addi-
tional sections were processed for immunolabeling of
PCNA and DCX using microwave antigen retrieval as
previously described [11,21]. Briefly, sections (thaw-
mounted on slides) were treated with 1% H2O2 in PBS
for 30 minutes, and pre-incubated in 5% normal rabbit
serum in PBS with 0.3% Triton X-100 for 30 minutes.
Sections were then incubated with PCNA (1:200) or
DCX (1:100) antibody. Sections were further reacted
with biotinylated rabbit anti-mouse (PCNA) or goat
(DCX) antibody at 1:400 concentration (BM0104 Boster
company, Santa Cruz Biotechnology ) for 2 hours, and
subsequently with the ABC reagent (1:400) (Vector
Laboratories, Burlingame, CA) for another 1 hour. The
immunoreactivity was then visualized by using DAB
(0.05%) and H2O2 (0.003%). Slides were then dipped in
hematoxylin, dehydrated and coverslippered.
For immunofluorescence, sections were incubated
with PCNA or DCX antibody overnight, washed exten-
sively and followed by a 2 hours reaction with Alexa
Fluor
® 488 conjugated donkey anti-mouse or anti-goat
IgGs (1:200, A21206 Invitrogen, Carlsbad, CA). Sections
were then washed and mounted with anti-fading med-
ium before examination on a laser confocal scanning
microscope (LSM 510 META; Zeiss, Germany). Sections
from every mouse in the recipient group were processed
Figure 5 Experimental design in the study. Mice with middle cerebral artery occlusion are divided into 4 groups: group#1: mice received G-
CSF (30 μg/kg/d, dissolved in 0.3 ml saline, i.p.) for 28 days and BMMC transplantation (1 × 10
7 cells dissolved in 0.3 ml saline) via tail vein, one
time on the first day after middle cerebral artery occlusion; group#2: mice received BMMC transplantation only (1 × 10
7 cells dissolved in 0.3 ml
saline); group#3: mice received G-CSF administration alone (30 μg/kg/d, dissolved in 0.3 ml saline, i.p.) for 28 days; and group#4 received 0.3 ml
saline (i.p.) for 28 days.
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tions in staining intensity.
Data and statistical analyses
All data are presented as mean ± standard deviation.
One set of sections from each animal was selected ran-
domly. In each frozen section, 10 microscopic fields
were captured randomly at a magnification of 200X. All
analyses were processed using the statistical software
GraphPad Prism 4. Means were compared using one-
way ANOVA with Bonferroni’s multiple comparison
tests. Statistical significance was set at a p value < 0.05.
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